These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25848521)

  • 21. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates.
    Seid RC; Sadoff JC
    J Biol Chem; 1981 Jul; 256(14):7305-10. PubMed ID: 6166612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
    Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
    Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine.
    An SJ; Woo JS; Chae MH; Kothari S; Carbis R
    Vaccine; 2015 Mar; 33(13):1614-9. PubMed ID: 25659268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection.
    Pressler T; Pedersen SS; Espersen F; Høiby N; Koch C
    Pediatr Pulmonol; 1992 Sep; 14(1):44-51. PubMed ID: 1437343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
    Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
    Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
    van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
    Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses.
    Johansen HK; Høiby N; Pedersen SS
    APMIS; 1991 Dec; 99(12):1061-8. PubMed ID: 1772641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats.
    Johansen HK; Hougen HP; Cryz SJ; Rygaard J; Høiby N
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1337-46. PubMed ID: 7551392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and characterization of gentiobiose heptaacetate conjugate vaccines that produce endotoxin-neutralizing antibodies.
    Bhattacharjee AK; Sadoff JC; Collins H; Cross AS; Khalil AH; Bieber MM; Wright C; Teng NN
    Bioconjug Chem; 1990; 1(6):375-80. PubMed ID: 2099185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
    Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
    Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
    Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model.
    Shams H; Heron I
    APMIS; 1998 May; 106(5):526-34. PubMed ID: 9674889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa.
    Farjaha A; Owlia P; Siadat SD; Mousavi SF; Shafieeardestani M
    J Biotechnol; 2014 Dec; 192 Pt A():240-7. PubMed ID: 25449544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.